Please login to the form below

Not currently logged in
Email:
Password:

Hearing loss prevention drugs expected by 2020

Report by Action on Hearing Loss launched today

hearing loss 

The first drugs to treat hearing conditions could be available as soon as 2020, according to a new report published today by charity Action on Hearing Loss (formerly RNID) entitled Hearing Progress.

The first-in-kind treatments strive to help alleviate some types of tinnitus, reduce hearing loss associated with loud noise exposure, middle ear infections and counter specific anti-cancer drugs that cause hearing loss.

Five drugs are currently in final stages of clinical testing while another thirteen are in the early stages of clinical development. 

Paul Breckell, chief executive at Action on Hearing Loss, commented: “Remarkable progress has been made bringing us to a point where there are a number of promising new treatments for hearing loss and tinnitus being clinically tested. We're about to enter a new exciting era where people confronting hearing loss won't just be limited to hearing aids and cochlear implants - drug treatments are within touching distance.

“Currently 10 million people in the UK have a hearing loss, which will increase to 14.5 million by 2031. As we're experiencing now with dementia, hearing loss is a potential public health crisis, so we will continue to fund research into new treatments.” 

The Hearing Progress report highlights the significant advancements made by the charity over the last 15 years as it works towards finding treatments to protect and restore hearing, silence tinnitus and improve modern technology.

Article by
Kirstie Pickering

16th April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics